Drug Profile
Research programme: anti-coronavirus antibodies - Vir Biotechnology
Alternative Names: 2019-nCoV - Vir Biotechnology; SARS-CoV - Vir Biotechnology; SARS-CoV-2 - Vir BiotechnologyLatest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Vir Biotechnology
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in COVID-2019-infections in USA (Parenteral)
- 28 Feb 2024 No recent reports of development identified for research development in COVID-2019-infections(Prevention) in USA (Parenteral)
- 30 Mar 2020 Generation Bio and Vir Biotechnology agree co-develop monoclonal antibodies for COVID-2019 infections